Evaluation of Efficacy of Hulba (Trigonellafoenumgraecum Linn.) in Rheumatoid Arthritis: A Randomized Control Trial
Abstract
The prevalence of the disease is approximately 0.5–1%. Rheumatoid arthritis has a large impact on patient’s quality of life and it has also been associated with a reduced life expectancy. Therefore, the study was conducted to evaluate the efficacy of Tukhm Hulba (Trigonellafoenumgraecum Linn.) in the management of rheumatoid arthritis. The study was carried out as a single, blind, randomized and standard controlled trial, to evaluate the efficacy of Tukhme Hulba (Trigonellafoenumgraecum Linn.) in the management of rheumatoid arthritis. Sixty diagnosed patients of rheumatoid arthritis according to American College of Rheumatology (ACR) criteria were included and randomly allocated to control and test groups; comprising 40 patients in test and 20 patients in control group. The test drug Tukhm Hulba was given to the test group in the form of tablet in the dose of 5 gm orally twice a day for 45 days, while the control group received Habbe Suranjan as a standard drug in the dose of two pills twice a day for 45 days. Rheumatoid arthritis patients were assessed for DAS28 score, subjective and objective parameters. The results were analysed statistically using Friedman test, Mann Whitney test, and paired ‘t’ test for intra group comparison, while Kruskal-Wallis test with Dunn’s multiple comparisons test, one way ANOVA with post-test for inter group comparison and CRP and RA factor were analysed by using Fisher’s extract test. The test drug exhibited significant effect on DAS28 score (p<0.01) and subjective parameters like morning stiffness (p<0.05), arthritis in three or more joints (p<0.05); while there was no effect on symmetrical arthritis. On objective parameters, there was no significant effect observed in ESR, CRP, RA factor and X-ray joints. The study revealed that the test drug exhibits good response on parameters such as DAS 28 score, morning stiffness and arthritis in three or more joints. Furthermore, no adverse effect was observed at the end of trial. Therefore, it may be concluded that the test drug is safe but not potentially effective in rheumatoid arthritis. Keywords: Rheumatoid arthritis, Tukhme Hulba, randomized controlled trialCite this Article Musta Ali, Siddiqui MA, Khan Javed A. Evaluation of Efficacy of Hulba (Trigonellafoenumgraecum Linn.) in Rheumatoid Arthritis: A Randomized Control Trial. Research & Reviews: A Journal of Biotechnology. 2016; 6(3): 27–34p.
Pubblicato
Fascicolo
Sezione
Licenza
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
· I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
· I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
· I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
· I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
_______________
We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
